Kidney tubular toxicity of maintenance pemetrexed therapy
- PMID: 21849225
- DOI: 10.1053/j.ajkd.2011.04.030
Kidney tubular toxicity of maintenance pemetrexed therapy
Abstract
Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer. Major side effects include myelosuppression and neutropenia. Three patients developed kidney disease while being treated with maintenance pemetrexed. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case. Kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy in all cases.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Secondary capillary leak syndrome related to pemetrexed exposure.Am J Kidney Dis. 2012 Apr;59(4):582-3; author reply 583. doi: 10.1053/j.ajkd.2011.12.031. Am J Kidney Dis. 2012. PMID: 22444494 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources